Rigel Pharmaceuticals Inc vs Berkshire Hathaway Inc
A head-to-head of Rigel Pharmaceuticals Inc (RIGL) and Berkshire Hathaway Inc (BRK-A) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | RIGL | BRK-A |
|---|---|---|
| Market Cap | $564.75M | $1.03T |
| P/E (TTM) | 1.50 | 15.41 |
| Forward P/E | 6.45 | 21.10 |
| P/S | 1.92 | 2.78 |
| P/B | 1.41 | 1.44 |
| EV/EBITDA | 3.51 | 0.00 |
| Dividend Yield | — | — |
| Profit Margin | 124.72% | 18.01% |
| Gross Margin | 93.33% | 23.63% |
| Operating Margin | 42.63% | 16.03% |
| Revenue Growth (YoY) | +21.19% | -3.94% |
| FCF Yield | 13.40% | 2.43% |
| Debt / Equity | 13.51 | 19.38 |
| Current Ratio | 2.42 | 6.75 |
Share:
Compare Rigel Pharmaceuticals Inc with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.